- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Xhosa
- Yiddish
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Tun bẹrẹ
Baofa Yu, MD Oloye Onisegun ni Ilu China, Ọjọgbọn Adjunct ni University of Texas (El Paso) (2016) ati Ọjọgbọn Adjunct ni Ile-ẹkọ giga ti Western University of Health Sciences (2016). O si graduated lati Peking Union Medical College (Peking Union Medical College) ni 1988. O je kan ranse si-dokita elegbe ni UCSD lati 1990 to 1991, Salk lati 1992 to 1993, Assistant Adjunct Ojogbon, UCSD lati 1994 to 1998 ni United States, o ti wa ni akọkọ ti oloro akàn ifijiṣẹ. isedale molikula. O ṣe agbekalẹ imọran tuntun ti lilo àsopọ tumo bi eto itusilẹ idaduro ti awọn oogun anticancer ati ọna itọju ti ifiomipamo itusilẹ idaduro, eyiti o ni iye ohun elo ile-iwosan, o tun pe ni lila ultro-kere ti ara ẹni intratumoral chemoimmunotherapy (UMIPIC). Ni ọdun 1998, o pada si Ilu China o si da Ile-iṣẹ Iwadi Shandong Baofa ati Ile-iwosan Akàn Taimei Baofa ni agbegbe igberiko Dongping pẹlu idoko-owo imọ-ẹrọ, ati pe o jẹ alaga ti Shandong Baofa Cancer Treatment Co., LTD., Ati nigbamii ti iṣeto Jinan Baofa Cancer Hospital (2004). Dongping Baofa General Hospital (2011), Beijing Baofa Cancer Hospital (2013) ati Immuno Oncology Systems, Inc. UMIPIC yii jẹ ailewu, rọrun lati ṣiṣẹ, ati atunṣe pẹlu anfani to dara fun gbogbo awọn tumo ti o lagbara. Loni a gba itọju ailera yii si "Awọn Itọsọna Isẹ Isẹgun fun Itọju Interventional ti To ti ni ilọsiwaju Pancreatic Cancer" (Iwadii) (iwadii 7th), ti a ṣe ni apapọ nipasẹ Kannada Anti-Cancer Association, National Clinical Research Centre for Radiology and Therapy, ati National Interventional Medicine Innovation Alliance, Journal of Clinical Radiology, iwọn didun 43,1 6 0.2 43,1 2 0.
O ti ṣe atẹjade diẹ sii ju awọn iwe 60 nipa itọju ailera yii ni Iseda: Iroyin Imọ-jinlẹ, Iwe akọọlẹ ti Cancer, J Basic Clin Pharma, J Immunological Sci, Iwe akọọlẹ Japanese ti Gastroenterology ati Hepatology, Awọn isunmọ aramada ni Ikẹkọ Akàn, Academic Journal of Engineering Studies, Nov Res Sci, Journal of Hepatocellular carcinoma, Target akàn, Aisan Liverrapy, Journal Iwe akọọlẹ Kannada ti Chest, Proc.Natl.Acad.Sci.USA, Pancreas ati awọn iwe iroyin miiran ati ọpọlọpọ awọn iwe ifiweranṣẹ kopa ninu AACR ati ipade ASCO.
Ilowosi pataki wa ni pe itọju itusilẹ idaduro ṣepọ awọn anfani ti chemotherapy ati ajẹsara, ati fun igba akọkọ, awọn mejeeji ti ni idapo ati lo si itọju ailera intratumoral nipasẹ ilowosi. O ṣepọ agbegbe ati itọju agbaye, ati mu ifọkansi ati akoko iṣe oogun pọ si nipasẹ itusilẹ iduroṣinṣin ti awọn oogun laarin tumọ, eyiti kii ṣe ipa ipa anticancer agbegbe nikan ti awọn oogun chemotherapy, ṣugbọn tun ṣe akiyesi ipa ti imunotherapy ti eto, nitorinaa ṣiṣe fun awọn aito ti awọn itọju ailera miiran, pese awọn imọran tuntun ati awọn isunmọ fun itọju akàn, pataki fun aarin ati awọn èèmọ to ti ni ilọsiwaju, pataki fun idinku ati gbigbe tumo tumo si tumo Itọju ailera UMPIC ni anfani ti lilo tumo bi orisun antigen ati ajesara autologous, eyiti o tun wa ni ila pẹlu aṣa idagbasoke ti Oogun Ti ara ẹni. Ati pe a lo si ile-iwosan, hapten ni idapo pẹlu awọn oogun kemoterapi fun itọju itusilẹ iduroṣinṣin ti aifọwọyi akọkọ ti akàn pancreatic, lakoko ti o nfa ipa ti o jinna, pataki ti eyiti o jẹ lati fa idahun ajẹsara, CD4 ti o ni ibatan T-cell, CD8, DC, T ati awọn sẹẹli NK, ati awọn autoantibodies tumor ti o ni ibatan B-cell: Awọn ọlọjẹ si P53, P16, Survival, P16, P16, P16, P53, P16, Surviva, P53, P16, P16, P53, P16, Survivin, P53, P16, C, P53, P16, C, P53, P16, C, P53, C, P53, P16, C, P53, C, P53, C, P53, C, P53, P16, Survivin, P53, P16, P53. p62, HCC1 ati awọn oncogenes miiran, eyi ni igba akọkọ lati rii pe T ati B ni ipa ninu idahun ti ajẹsara, ati awọn iṣẹ ile-iwosan ti ipa jijinna ati pe a yan itọju ailera yii fun “Awọn Itọsọna Isẹgun fun Itọju Interventional ti Akàn Pancreatic To ti ni ilọsiwaju” (Iwadii) (ẹda 7th) ni apapọ ti a ṣe agbekalẹ nipasẹ Ile-iṣẹ Anti-Cancer ti Orilẹ-ede Kannada ati Ile-iṣẹ Iṣoogun ti Orilẹ-ede ti Orilẹ-ede, Ile-iṣẹ Iṣoogun Anti-Cancer ti Orilẹ-ede. Alliance Innovation Medicine jẹ atẹjade ni Iwe irohin ti Radiology Clinical, iwọn didun 43, nọmba 19, 2024, 1636-1648.
Awọn itọkasi:
| Odun | Akọle Abala | Atẹjade |
| 2015 | Ipa itọju ailera ti o ni ilọsiwaju ni awọn ipele ilọsiwaju ti akàn ẹdọfóró nipasẹ lila ultra-kere ti ara ẹni intratumoral | Ẹdọfóró akàn: Àkọlé ati Therapy, 2015; 6 1-11 |
| 2015 | Idabobo deede lati le pa akàn naa dara julọ | 2015 Awọn onkọwe. Oogun akàn ti a gbejade nipasẹ John Wiley & Sons Ltd.1349-1403 |
| 2015 | Awọn ailagbara ati awọn ọgangan ti Lilo Awọn eku ati Awọn eku ni Awọn Iwadi Chemoprevention Cancer | Iwe akosile ti akàn 2015; 6 (10): 1058-1065.doi: 10.7150/jca.12519 |
| 2015 | Akoko iwalaaye gbogbogbo ti o ni ilọsiwaju ti o ni ilọsiwaju ninu ẹdọforo ti ẹdọforo ti ilọsiwaju nipasẹ lila-kere-kere ti ara ẹni intratumoral chemoimmunotherapy | Iwe akosile ti Ẹjẹ Ẹjẹ-ẹjẹ, 2015: 2, 1-12 |
| 2015 | Lilo awọn oogun Catatonic apapọ Hapten fun Imudara Ipa Itọju ailera ni Awọn ipele Ilọsiwaju ti Akàn Pancreatic | Iwe akosile ti Iwadi Ẹdọ, Awọn ailera & Itọju ailera, 2015,1 (3): 013-23 |
| 2016 | Kọ ẹkọ nipa Pataki ti Idena Iyipada lati Awọn aarun Arun Iwosan ati Awọn èèmọ Awujọ | Iwe akosile ti Akàn 2016; 7 (4): 436-445. doi: 10.7150 / jca.13832 |
| 2016 | Anfani Iwalaaye Lapapọ Hapten ni ilọsiwaju ni Awọn ipele ti o pẹ ti Akàn Ẹdọfóró Ẹdọfóró Ẹdọfóró Kekere (NSCLC) nipasẹ Itọju Itọju Ẹjẹ Intratumoral Kemoral Chemo Immunotherapy (UMIPIC) Pẹlu ati laisi Itọju Radiation Fi iwe afọwọkọ silẹ | Iwe akosile ti Idena Akàn & Iwadi lọwọlọwọ 2016, 4 (2): 00116 |
| 2020 | Ọna Imudaniloju Aramada Kan fun Itọju Ẹjẹ Akàn pẹlu Ọbẹ Liquid & Immuno Therapy: UMIPIC, o le bori ọpọlọpọ iṣẹ abẹ, kimoterapi ati Itọju Radiation fun gbogbo Awọn ipele ti Tumor to lagbara | Aramada yonuso ni akàn Study NACS.000590. 4(3).2020 |
| 2020 | Oògùn Ti a dapọ nipasẹ H2O2 Injection Intratumoral si titan Matrix Extracellular kan sinu Coagulum Aifọwọyi bi Ibi ipamọ Oògùn | Aramada Iwadi ni sáyẹnsì NRS.000584. 4(2).2020 |
| 2020 | Ireti Tuntun fun Itọju Ẹjẹ Akàn pẹlu Ọbẹ Liquid & Itọju Immuno: UMIPIC | Awọn aṣa lọwọlọwọ ni Ile-iwosan & Awọn sáyẹnsì Iṣoogun ISSN:2689-4246 Ọjọ Atẹjade: Oṣu Kẹta Ọjọ 20, Ọdun 2020 |
| 2022 | Iredodo Tumor nla pẹlu CD4/8+ ati CD11+ Imudara Akoko Iwalaaye Gigun ni Awọn ipele To ti ni ilọsiwaju ti gbogbo awọn èèmọ Ri to nipasẹ Ultra Kere Lila Ti ara ẹni Intratumoral Chemoimmunotehrapy | Iwe akọọlẹ Japanese ti Gastroenterology ati Hepatology |
| 2022 | Iredodo nla kan pẹlu Ifihan pataki ti CD11 & CD4 Ṣe agbejade Ipa Abscopal nipasẹ Injection Intramoral Chemotherapy Drug with Hapten in Animal Awoṣe | Iwe akosile ti Awọn sáyẹnsì Ajẹsara |
| 2022 | Akoko Tuntun ti Iṣẹ abẹ Immuno ti n bọ: Ọna-ara Eclectic Aramada fun Itọju Akàn pẹlu Ọbẹ Liquid & Itọju Immuno | Iwe akọọlẹ ti Awọn ẹkọ Imọ-ẹrọ |
| 2022 | Iredodo Tumor nla pẹlu CD4/8+ ati CD11+ Mu Ipa Iwalaaye Gigun nipasẹ Injection Intratumral Idarapọ Ti o dara julọ ti Awọn oogun Chemotherapy pẹlu Hydralazine bi o ti ṣẹlẹ ni Awoṣe Eranko | Iwe akọọlẹ Japanese ti Gastroenterology ati Hepatology |
| 2023 | Ji Awọn sẹẹli Ajẹsara Jiini nipasẹ Hapten Imudara Intratumoral Chemotherapy pẹlu Penicillin Gigun Iwalaaye Akàn Pancreatic Pancreatic | Iwe akosile ti Akàn 2023; 14 (8): 1282-1292 |
| 2023 | Ifojusi aṣeyọri ni ipo ti antijeni iparun oncogenic nipasẹ hapten induced tumor to somọ autoantibodies (iTAA) | portfolio iseda Awọn ijabọ Imọ-jinlẹ iwọn didun 13, Nọmba Abala: 9902 (2023) |
| 2023 | Awọn Iyipada Ajẹsara ti o fa nipasẹ Intratumoral Hapten Plus Awọn oogun Kemoterapi ti EndometrialCancer | Iwe akosile ti Ile-iwosan Ipilẹ ati Ile-iwosan Keje 31,2023. DOI: 10.37532/0976-0113.14 (S1).17 |
| 2023 | Igbaradi Ajẹsara Akàn ati Iṣiṣẹ Awọn sẹẹli Ajẹsara nipasẹ Kimoterapi Imudara Hapten ni Akàn Ẹdọfóró akọkọ | Iwe akosile ti Ile-iwosan Ipilẹ ati Ile-iwosan Oṣu Kẹjọ 11, Ọdun 2023. DOI: 10.37532/0976-0113.14 (S1).18 |
| 2023 | scRNA-Seq Analysis Iyipada Ajẹsara ti Intratumoral Hapten Plus Awọn oogun Chemotherapy fun Itọju Akàn Ọyan Ọkunrin | IWE IWE AJẸ AJẸ AWỌN ỌJỌ AWỌN ỌJỌ ATI IṢẸRỌ IṢẸRỌ ỌJỌ 27 Oṣu kọkanla, Ọdun 2023. DOI:10.26502/jcsct.5079214 |
| 2024 | Ipa ti iṣuu soda stibogluconate ni igbanisiṣẹ ati ijidide awọn sẹẹli ajẹsara ninu omi pleural ti igbaradi akàn pancreatic fun imunotherapy | Awọn iwaju ni Imunoloji January 19, 2024. DOI:10.3389/fimmu.2023.1315468 |
| 2024 | Itọju ailera Ajẹsara Kemikali ti Hapten-Hapten pẹlu Isakoso Oògùn sinu akàn cervical laisi Hysterectomy | Iwe akosile ti Iṣẹ abẹ Okudu 13, 2024. DOI: 10.29011 / 2575-9760.11063 |
| 2024 | Lo Profaili scRNA-Seq lati Ṣetumo Idahun Ajẹsara lẹhin Itumọ inu Hapen Imudara Chemotherapy lori Ọran ti Intracranial Anaplastic Hemangiopericytoma Metastasis Ẹdọ: Ijabọ ọran kan | Iwe akosile ti Iṣẹ abẹ Okudu 10, 2024. DOI: 10.29011 / 2575-9760.11063 |
